Chronic naltrexone treatment increases expression of preproenkephalin and preprotachykinin mRNA in discrete brain regions - PubMed (original) (raw)

Chronic naltrexone treatment increases expression of preproenkephalin and preprotachykinin mRNA in discrete brain regions

A Tempel et al. J Neurosci. 1990 Mar.

Abstract

Long-term blockade of brain opioid receptors by the opiate antagonist naltrexone increases methionine-enkephalin content in the striatum and nucleus accumbens (Tempel et al., 1984). To determine whether these changes in peptide levels reflect increased peptide synthesis, we examined preproenkephalin mRNA content in discrete brain regions of control (placebo-treated) and chronic naltrexone-treated animals by Northern analysis. Chronic naltrexone treatment (8 d) led to an approximately 12-fold increase in the striatal content of preproenkephalin mRNA relative to that of control animals. In contrast, no statistically significant change was observed in striatal mRNA for cyclophilin (1B15) or actin. Small increases in preproenkephalin mRNA content occurred in the hippocampus (+40%) and hypothalamus (+19%). No significant changes occurred in the frontal cortex. Increases in levels of the mRNA were seen as early as 24 hr after antagonist treatment. In contrast, changes in opioid receptor density required 3-4 d to reach half-maximal up-regulation after chronic antagonist treatment. Recent evidence has suggested that substance P is regulated by opioid peptides. To determine whether substance P synthesis is altered by chronic antagonist treatment, the mRNA corresponding to the precursor for substance P was examined using a probe for exon-7 of the preprotachykinin gene. Preprotachykinin mRNA content in the striatum was increased 6-fold after chronic antagonist treatment relative to that of control animals. Substance P content was increased 3-fold after chronic antagonist treatment. These data suggest that chronic blockade of brain opioid receptors leads to the increased synthesis of both enkephalin and substance P in the striatum and that these changes are relatively specific.(ABSTRACT TRUNCATED AT 250 WORDS)

PubMed Disclaimer

Cited by

Substance P is expressed in hippocampal principal neurons during status epilepticus and plays a critical role in the maintenance of status epilepticus.
Liu H, Mazarati AM, Katsumori H, Sankar R, Wasterlain CG. Liu H, et al. Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):5286-91. doi: 10.1073/pnas.96.9.5286. Proc Natl Acad Sci U S A. 1999. PMID: 10220458 Free PMC article.
Regulation of neuropeptide expression in the brain by neurotrophins. Potential role in vivo.
Carnahan J, Nawa H. Carnahan J, et al. Mol Neurobiol. 1995 Apr-Jun;10(2-3):135-49. doi: 10.1007/BF02740672. Mol Neurobiol. 1995. PMID: 7576304 Review.
Morphine and naltrexone modulate D2 but not D1 receptor induced motor behavior in MPTP-lesioned monkeys.
Vermeulen RJ, Drukarch B, Sahadat MC, Goosen C, Schoffelmeer AN, Wolters EC, Stoof JC. Vermeulen RJ, et al. Psychopharmacology (Berl). 1995 Apr;118(4):451-9. doi: 10.1007/BF02245946. Psychopharmacology (Berl). 1995. PMID: 7568632
Low-Dose Naltrexone in Rheumatological Diseases.
de Carvalho JF, Skare T. de Carvalho JF, et al. Mediterr J Rheumatol. 2023 Mar 31;34(1):1-6. doi: 10.31138/mjr.34.1.1. eCollection 2023 Mar. Mediterr J Rheumatol. 2023. PMID: 37223594 Free PMC article. Review.
Substance P Regulation in Epilepsy.
Chi G, Huang Z, Li X, Zhang K, Li G. Chi G, et al. Curr Neuropharmacol. 2018;16(1):43-50. doi: 10.2174/1570159X15666170504122410. Curr Neuropharmacol. 2018. PMID: 28474564 Free PMC article. Review.

Chronic naltrexone treatment increases expression of preproenkephalin and preprotachykinin mRNA in discrete brain regions - PubMed (original) (raw)